Bristol-Myers to buy Celgene in $74B deal

Bristol-Myers Squibb Company and Celgene Corporation announce that they have entered into a merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.
03:21
Thu, Jan 3 20197:03 AM EST